{
  "id": "mhgap#risk_safety_d0da9caa",
  "content": "y Evidence regarding the safety and effectiveness\nfunctioning (moderate-certainty evidence) and\nof fluphenazine is mainly concerning the long-\nquality of life (very low-certainty evidence) were\nacting injectable formulations. Please refer to PSY4\nalso improved.\nrecommendations for further information.\ny Antipsychotics were associated with various\ny This recommendation does not suggest that only\nside-effects (very low- to low-certainty evidence)\nmedicine should be offered, but medicine may be\nincluding movement disorders, weight gain,\noffered in combination with psychotherapy. Please\nmetabolic side-effects, prolactin increase, sexual\nrefer to PSY11 for further information.\nside-effects, QT prolongation, sedation, which\nall appear in varying degrees. The propensity\n88\n3. Recommendations\nResearch gaps y Acquisition costs can differ substantially and also\ny Data on first-generation antipsychotics with few throughout the world. Recent antipsychotics\nexceptions such as haloperidol and chlorpromazine may have currently higher costs than some\nwere very limited. As these medicines are of lower older antipsychotics.\ncost, further trials on some of them with relevant y Disruption in medicine supply (common in LMICs)\npharmacological properties would be warranted. may interfere with continuation of treatment.\ny For the treatment of psychotic disorders, the WHO\nImplementation considerations\nEML (13) includes the following oral medicines:",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety y Evidence regarding the safety and effectiveness\nfunctioning (moderate-certainty evidence) and\nof fluphenazine is mainly concerning the long-\nquality of life (very low-certainty evidence) were\nacting injectable formulations. Please refer to PSY4\nalso improved.\nrecommendations for further information.\ny Antipsychotics were associated with various\ny This recommendation does not suggest that only\nside-effects (very low- to low-certainty evidence)\nmedicine should be offered, but medicine may be\nincluding movement disorders, weight gain,\noffered in combination with psychotherapy. Please\nmetabolic side-effects, prolactin increase, sexual\nrefer to PSY11 for further information.\nside-effects, QT prolongation, sedation, which\nall appear in varying degrees. The propensity\n88\n3. Recommendations\nResearch gaps y Acquisition costs can differ substantially and also\ny Data on first-generation antipsychotics with few throughout the world. Recent antipsychotics\nexceptions such as haloperidol and chlorpromazine may have currently higher costs than some\nwere very limited. As these medicines are of lower older antipsychotics.\ncost, further trials on some of them with relevant y Disruption in medicine supply (common in LMICs)\npharmacological properties would be warranted. may interfere with continuation of treatment.\ny For the treatment of psychotic disorders, the WHO\nImplementation considerations\nEML (13) includes the following oral medicines: Y evidence regarding the an toàn and effectiveness\nfunctioning (moderate-certainty evidence) and\nof fluphenazine is mainly concerning the long-\nquality of life (very low-certainty evidence) were\nacting injectable formula..."
}